The FDA has approved ruxolitinib (Jakafi, Incyte) for myelofibrosis, a rare bone marrow disease. The agent inhibits the JAK1 and JAK2 enzymes, which play a role in blood regulation and immunological functioning.
Advertisement
Advertisement
Jan 31, 2012
The FDA has approved ruxolitinib (Jakafi, Incyte) for myelofibrosis, a rare bone marrow disease. The agent inhibits the JAK1 and JAK2 enzymes, which play a role in blood regulation and immunological functioning.
Source: FDA.
For more on the approval, visit www.fda.gov/NewsEvents.